Medicare beneficiary barriers to genetic counselor services: Implications for patient policy, decision‐making , and care
Journal of Genetic Counseling · 2024-04 · 33 (2) · 262-268
DOI: 10.1002/jgc4.1729 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Genetic Counseling, online erschienen am 28.05.2023. Verfasst von Sara Riordan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Unified Patient Network, Charlestown, Massachusetts, USA. Hauptthemen laut MEDLINE: Genetic Counseling, Medicare. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: AstraZeneca, Merck.
Abstract (Originalsprache)
If passed, the “Access to Genetic Counselor Services Act” will authorize genetic counselors to provide services under Medicare part B. We assert that Medicare policy should be updated through the enactment of this legislation to provide Medicare beneficiaries with direct access to genetic counselor services. In this article, we discuss the background, history, and some recent research relevant to patient access to genetic counselors to provide context and perspective regarding the rationale, justification, and potential results of the proposed legislation. We outline the potential impact of Medicare policy reform, including the effect on access to genetic counselors in high‐demand areas or underserved communities. Although the proposed legislation pertains only to Medicare, we argue that private systems will also be impacted by passage as this may lead to an increase in hiring and retention of genetic counselors by health systems, thereby improving access to genetic counselors across the US.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unified Patient Network, Charlestown, Massachusetts, USA.
- National Society of Genetic Counselors, Washington, District of Columbia, USA.
- Department of Genetics, Cell Biology, and Development, University of Minnesota, Minneapolis, Minnesota, USA.
- Guidehouse Inc., McLean, Virginia, USA.
- Center for Observational and Real-World Evidence (CORE), Merck & Co. Inc., Kenilworth, New Jersey, USA.
- AstraZeneca Pharmaceuticals, Gaithersburg, Maryland, USA.
ORCID-Profile: Sara Riordan, Heather Zierhut, Bradley L Goodnight
Förderung
- AstraZeneca
- Merck
Zitieren
APA
Riordan, S., Richardson, J., Zierhut, H., Goodnight, B. L., Sieling, F. H., Black, C. M., & Moore, R. A. (2024). Medicare beneficiary barriers to genetic counselor services: Implications for patient policy, decision‐making , and care. Journal of Genetic Counseling, 33(2), 262-268. https://doi.org/10.1002/jgc4.1729
Vancouver
Riordan S, Richardson J, Zierhut H, Goodnight BL, Sieling FH, Black CM, et al. Medicare beneficiary barriers to genetic counselor services: Implications for patient policy, decision‐making , and care. Journal of Genetic Counseling. 2024;33(2):262-268. doi:10.1002/jgc4.1729
BibTeX
@article{Riordan2024,
author = {Riordan, Sara and Richardson, John and Zierhut, Heather and Goodnight, Bradley L and Sieling, Fred H and Black, Christopher M and Moore, Rebekah A},
title = {Medicare beneficiary barriers to genetic counselor services: Implications for patient policy, decision‐making , and care},
journal = {Journal of Genetic Counseling},
year = {2024},
volume = {33},
number = {2},
pages = {262--268},
doi = {10.1002/jgc4.1729}
}
EUVIMED